GlassScriptPhysician profile
Allan David Moser
NPI 1588045116
$524.70
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $453 · 2020: $71.75.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $184.25 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $83.43 | 2019 | |
| Glaxosmithkline, LLC. | $51.46 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.26 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.68 | 2019 | |
| Amgen INC. | $24.61 | 2019 | |
| Astellas Pharma US INC | $17.83 | 2019 | |
| Abbvie INC. | $15.15 | 2019 | |
| Pfizer INC. | $13.71 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.01 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.01 | 2019 | |
| Merck Sharp & Dohme LLC | $11.67 | 2019 | |
| Aegerion Pharmaceuticals, INC. | $11.51 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.25 | 2019 | |
| Shire North American Group INC | $10.87 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allan Moser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.